Chris Wai Hang Lo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chris Wai Hang Lo has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Cathryn M. Lewis
Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
14 shared publications - Alexandra Claire Gillett
Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London
6 shared publications - Michelle Kamp
Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
6 shared publications - Oliver Pain
Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
6 shared publications - Dale Handley
Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London
4 shared publications - Madhurbain Singh
Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
4 shared publications
Latest Publications
- Open Access
Genetic architecture and polygenic prediction of self-reported response to selective serotonin reuptake inhibitors in individuals with depression: a genome-wide meta-analysis
Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for depression, but response is highly variable, and no robust genetic predictors have been identified. We conducted a genome-wide association meta-analysis of self-reported SSRI response in 62,879 individuals of European ancestry with depression (72.6% responders) across six cohorts (seven datasets), followed by gene-set, transcriptomic, proteomic, drug-target and polygenic score (PGS) analyses. SNP-based heritability was modest but significant (h² = 3.1%, SE = 1.4%) with no genome-wide significant variants detected. Gene-set analyses implicated gamma-aminobutyric acid (GABA)ergic and glutamatergic neurotransmission, and a gene involved in glutamate transport ( SLC17A6 ) showed consistent sub-threshold evidence across pathway, transcriptomic and proteomic analyses. Drug-target enrichment for hypnotics, anxiolytics and general anesthetics further supported the GABAergic signal. A leave-one-out PGS from the discovery meta-analysis was associated with self-reported SSRI response in independent cohorts (meta-analysis OR=1.05, 95% CI 1.02–1.08, p=0.002). Higher PGS for depression, attention-deficit/hyperactivity disorder (ADHD), anxiety, post-traumatic stress disorder (PTSD), autism, addiction and schizophrenia were associated with lower odds of reported SSRI response, with ADHD, PTSD, autism and addiction remaining after adjustment for depression PGS. In contrast, educational attainment PGS was associated with better SSRI response. Self-reported SSRI response captures genetic insights relevant to antidepressant response, implicating GABAergic and glutamatergic neurotransmission. Individuals with higher genetic loading for psychiatric conditions report poorer response, and higher genetic loading for educational attainment PGS a better reported response. Although larger studies are needed to identify specific variants, self-report offers a practical, patient-centered and scalable route to collect the larger samples required.
Open AccessGenetic architecture and polygenic prediction of self-reported response to selective serotonin reuptake inhibitors in individuals with depression: a genome-wide meta-analysis
Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for depression, but response is highly variable, and no robust genetic predictors have been identified. We conducted a genome-wide association meta-analysis of self-reported SSRI response in 62,879 individuals of European ancestry with depression (72.6% responders) across six cohorts (seven datasets), followed by gene-set, transcriptomic, proteomic, drug-target and polygenic score (PGS) analyses. SNP-based heritability was modest but significant (h² = 3.1%, SE = 1.4%) with no genome-wide significant variants detected. Gene-set analyses implicated gamma-aminobutyric acid (GABA)ergic and glutamatergic neurotransmission, and a gene involved in glutamate transport ( SLC17A6 ) showed consistent sub-threshold evidence across pathway, transcriptomic and proteomic analyses. Drug-target enrichment for hypnotics, anxiolytics and general anesthetics further supported the GABAergic signal. A leave-one-out PGS from the discovery meta-analysis was associated with self-reported SSRI response in independent cohorts (meta-analysis OR=1.05, 95% CI 1.02–1.08, p=0.002). Higher PGS for depression, attention-deficit/hyperactivity disorder (ADHD), anxiety, post-traumatic stress disorder (PTSD), autism, addiction and schizophrenia were associated with lower odds of reported SSRI response, with ADHD, PTSD, autism and addiction remaining after adjustment for depression PGS. In contrast, educational attainment PGS was associated with better SSRI response. Self-reported SSRI response captures genetic insights relevant to antidepressant response, implicating GABAergic and glutamatergic neurotransmission. Individuals with higher genetic loading for psychiatric conditions report poorer response, and higher genetic loading for educational attainment PGS a better reported response. Although larger studies are needed to identify specific variants, self-report offers a practical, patient-centered and scalable route to collect the larger samples required.
- Open Access
Clinical, sociodemographic, and genetic predictors of depressive episode duration in the UK Biobank
Background: The course of major depressive disorder is heterogeneous, with UK Biobank (UKB) participants reporting episode durations ranging from 24 months. Here, we identify predictors of episode duration, characterise its genetic architecture, and examine links to treatment seeking and response. Methods: In UKB participants meeting criteria for major depressive disorder, we examined clinical, sociodemographic, and genetic predictors of short (0-3 months) and long (>24 months) episode duration, fitted in predictor-specific, domain-level, and combined models. We also conducted genome-wide association studies in European-ancestry participants (n = 40,858) and estimated common-variant heritability. Results: Clinical features were most informative: higher childhood trauma scores, a stressful trigger, and recurrence showed the most consistent associations with short and long durations across models (OR combined : short = 0.75-0.95; long = 1.13-1.45; all p≤0.02). Higher neuroticism scores were also associated with both durations (OR combined : short = 0.977; long = 1.053; p<0.001). Polygenic risk for depression was associated with episode duration, though its independent contribution was modest. Long episodes were more predictable than short in validation analyses (AUC = 0.705 vs 0.601) and were associated with greater treatment engagement but lower perceived benefit; SNP-based heritability was nominally significant. Conclusions: Clinical features captured most of the predictable variance in episode duration, with the same predictors largely operating in opposite directions for short and long episodes, consistent with a continuum of chronicity. Those at risk for long episodes emerge as a priority for early identification and intervention.
Open AccessClinical, sociodemographic, and genetic predictors of depressive episode duration in the UK Biobank
Background: The course of major depressive disorder is heterogeneous, with UK Biobank (UKB) participants reporting episode durations ranging from 24 months. Here, we identify predictors of episode duration, characterise its genetic architecture, and examine links to treatment seeking and response. Methods: In UKB participants meeting criteria for major depressive disorder, we examined clinical, sociodemographic, and genetic predictors of short (0-3 months) and long (>24 months) episode duration, fitted in predictor-specific, domain-level, and combined models. We also conducted genome-wide association studies in European-ancestry participants (n = 40,858) and estimated common-variant heritability. Results: Clinical features were most informative: higher childhood trauma scores, a stressful trigger, and recurrence showed the most consistent associations with short and long durations across models (OR combined : short = 0.75-0.95; long = 1.13-1.45; all p≤0.02). Higher neuroticism scores were also associated with both durations (OR combined : short = 0.977; long = 1.053; p<0.001). Polygenic risk for depression was associated with episode duration, though its independent contribution was modest. Long episodes were more predictable than short in validation analyses (AUC = 0.705 vs 0.601) and were associated with greater treatment engagement but lower perceived benefit; SNP-based heritability was nominally significant. Conclusions: Clinical features captured most of the predictable variance in episode duration, with the same predictors largely operating in opposite directions for short and long episodes, consistent with a continuum of chronicity. Those at risk for long episodes emerge as a priority for early identification and intervention.
- Open Access
Trans-ancestry genome-wide association meta-analysis of antidepressant response to selective serotonin reuptake inhibitors in clinical studies of depression
Antidepressants are widely prescribed for major depressive disorder, yet only one-third of patients achieve remission after initial treatment. Previous genome-wide association studies (GWAS) of clinically assessed antidepressant response combined multiple antidepressant classes, potentially obscuring class-specific effects. This study focused on selective serotonin reuptake inhibitors (SSRIs), often first-line due to better tolerability. Data from 15 cohorts across four ancestries were integrated: European (N = 3887; 11 studies), East Asian (N = 1068; 4), African (N = 277; 1), and Admixed American (N = 250; 1). GWAS of non-remission and percentage improvement were conducted within cohorts, followed by ancestry-specific meta-analyses and trans-ancestry meta-regression. Single nucleotide polymorphism (SNP)-based heritability was estimated in European samples. Polygenic scores were used for leave-one-out prediction and to assess shared genetic architecture with psychiatric traits. Gene-level and gene-set enrichment analyses were also performed. No genome-wide significant variants were identified for either outcome in any ancestry-specific or trans-ancestry analyses. However, trans-ancestry meta-regression yielded eight independent loci with suggestive associations (p < 1 × 10 −5 ) for non-remission and 17 for percentage improvement. Gene-set analyses revealed nominal enrichment of the serotonergic synapse pathway for non-remission. SNP-based heritability estimates were not significantly different from zero for either outcome. Better SSRI response was nominally associated with lower genetic predisposition to major depressive disorder, post-traumatic stress disorder, and schizophrenia. This study represents the largest trans-ancestry GWAS of SSRI response, highlighting emerging biological signals. Limited power emphasises the need for larger and ancestrally diverse cohorts to better characterise the genetic architecture of antidepressant response.
Open AccessTrans-ancestry genome-wide association meta-analysis of antidepressant response to selective serotonin reuptake inhibitors in clinical studies of depression
Antidepressants are widely prescribed for major depressive disorder, yet only one-third of patients achieve remission after initial treatment. Previous genome-wide association studies (GWAS) of clinically assessed antidepressant response combined multiple antidepressant classes, potentially obscuring class-specific effects. This study focused on selective serotonin reuptake inhibitors (SSRIs), often first-line due to better tolerability. Data from 15 cohorts across four ancestries were integrated: European (N = 3887; 11 studies), East Asian (N = 1068; 4), African (N = 277; 1), and Admixed American (N = 250; 1). GWAS of non-remission and percentage improvement were conducted within cohorts, followed by ancestry-specific meta-analyses and trans-ancestry meta-regression. Single nucleotide polymorphism (SNP)-based heritability was estimated in European samples. Polygenic scores were used for leave-one-out prediction and to assess shared genetic architecture with psychiatric traits. Gene-level and gene-set enrichment analyses were also performed. No genome-wide significant variants were identified for either outcome in any ancestry-specific or trans-ancestry analyses. However, trans-ancestry meta-regression yielded eight independent loci with suggestive associations (p < 1 × 10 −5 ) for non-remission and 17 for percentage improvement. Gene-set analyses revealed nominal enrichment of the serotonergic synapse pathway for non-remission. SNP-based heritability estimates were not significantly different from zero for either outcome. Better SSRI response was nominally associated with lower genetic predisposition to major depressive disorder, post-traumatic stress disorder, and schizophrenia. This study represents the largest trans-ancestry GWAS of SSRI response, highlighting emerging biological signals. Limited power emphasises the need for larger and ancestrally diverse cohorts to better characterise the genetic architecture of antidepressant response.
- Open Access
- 24 April 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Treatment resistant depression in electronic health records: definitions matter
Background: Many people with depression do not respond well to the first antidepressant prescribed. Treatment Resistant Depression (TRD) refers to depression which does not respond to multiple subsequent antidepressant treatments. Identifying TRD in routinely-collected health records is challenging due to limited response-related data. Previous studies have used definitions based on the number of antidepressant switches observed. However, these do not account for other features clinically indicative of treatment resistance, such as augmentation of antidepressants with lithium or antipsychotics and switches between antidepressant classes. This study examined definitions of TRD and their impact on the resulting sample across three cohorts. Methods: Across the DataLoch, UK Biobank, and Generation Scotland cohorts, we identified cases of depression from primary and secondary care record codes and extracted antidepressant treatment patterns from dispensing/prescribing records ( N = 51,283, N = 10,556, and N = 649 respectively). We examined 9 TRD definitions that varied along two axes: the minimum number of switches required (1+, 2 + or 3 + switches), and the inclusion of other clinical features (augmentation and one or more between-class switches) as alternative routes to TRD. We contrasted sample size and characteristics between definitions, and examined factors associated with inclusion versus a reference definition of 2 + switches. Results: The reference TRD definition included 10% of depression cases in the routine data collection, but substantially fewer cases (4%) in consented cohorts. More inclusive definitions that required fewer switches or included a between-class switch classified more individuals as TRD, but resulted in a proportionally older, more deprived sample with fewer depression-related health record codes, older age of depression onset, lower symptom severity, and greater use of first-line antidepressants. Requiring more switches (3 + switches) classified fewer individuals as TRD, but resulted in a proportionally younger sample, with more depression-related health record codes, younger age of depression onset, and greater use of antidepressants associated with later in the treatment line (e.g., Tricyclics). Definitions including augmentations resulted in a small increase in sample size without notable change in sample characteristics. Conclusions: TRD is underrepresented in consented cohort studies. A definition of TRD that includes 2 + antidepressant switches or augmented antidepressant treatment as indicators balances sample size with depression severity, while incorporating features from real-world treatment journeys. Clinical trial number: Not applicable.
- 24 April 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Open AccessTreatment resistant depression in electronic health records: definitions matter
Background: Many people with depression do not respond well to the first antidepressant prescribed. Treatment Resistant Depression (TRD) refers to depression which does not respond to multiple subsequent antidepressant treatments. Identifying TRD in routinely-collected health records is challenging due to limited response-related data. Previous studies have used definitions based on the number of antidepressant switches observed. However, these do not account for other features clinically indicative of treatment resistance, such as augmentation of antidepressants with lithium or antipsychotics and switches between antidepressant classes. This study examined definitions of TRD and their impact on the resulting sample across three cohorts. Methods: Across the DataLoch, UK Biobank, and Generation Scotland cohorts, we identified cases of depression from primary and secondary care record codes and extracted antidepressant treatment patterns from dispensing/prescribing records ( N = 51,283, N = 10,556, and N = 649 respectively). We examined 9 TRD definitions that varied along two axes: the minimum number of switches required (1+, 2 + or 3 + switches), and the inclusion of other clinical features (augmentation and one or more between-class switches) as alternative routes to TRD. We contrasted sample size and characteristics between definitions, and examined factors associated with inclusion versus a reference definition of 2 + switches. Results: The reference TRD definition included 10% of depression cases in the routine data collection, but substantially fewer cases (4%) in consented cohorts. More inclusive definitions that required fewer switches or included a between-class switch classified more individuals as TRD, but resulted in a proportionally older, more deprived sample with fewer depression-related health record codes, older age of depression onset, lower symptom severity, and greater use of first-line antidepressants. Requiring more switches (3 + switches) classified fewer individuals as TRD, but resulted in a proportionally younger sample, with more depression-related health record codes, younger age of depression onset, and greater use of antidepressants associated with later in the treatment line (e.g., Tricyclics). Definitions including augmentations resulted in a small increase in sample size without notable change in sample characteristics. Conclusions: TRD is underrepresented in consented cohort studies. A definition of TRD that includes 2 + antidepressant switches or augmented antidepressant treatment as indicators balances sample size with depression severity, while incorporating features from real-world treatment journeys. Clinical trial number: Not applicable.
- Open Access
Clustering of major depressive disorder genetic instruments identifies distinct and directionally opposing effects on cardiometabolic risk
Background Major depressive disorder (MDD) is a highly heterogeneous condition that is frequently co-morbid with type 2 diabetes (T2D), and yet the biological mechanisms linking these diseases remain unclear. We aim to identify distinct biological pathways in depression that may modify T2D risk. Methods Using Clustered Mendelian randomisation (MR-Clust), we analysed 621 genome-wide significant MDD variants to identify clusters of variants with similar causal effects on T2D. These clusters were validated, and their causal effects were comprehensively tested against glycaemic traits, depression subtypes, T2D risk factors, and cardiometabolic biomarkers using external GWAS data and the UK Biobank. Functional annotation of these clusters was performed using FUMA. Results MR-Clust identified three distinct clusters of MDD-associated variants. Two clusters (MDD1 and MDD2) were causal for higher T2D and its related risk factors, adverse glycaemic and cardiometabolic profiles. Functional annotation implicated brain expression that overlapped strongly with depression-related traits such as smoking and neuroticism. By contrast, MDD3 was causal for lower T2D risk, more favourable glycaemic and cardiometabolic biomarker profiles, and was enriched for gene sets linked to fatty acid metabolism and steroid biosynthesis. MDD1 and MDD2 clusters were associated with atypical-like depression symptoms, whereas MDD3 was associated with melancholic depression symptoms. Conclusion Our findings demonstrate a heterogenous genetic architecture for depression, with distinct biological pathways conferring opposing effects on cardiometabolic health. Understanding this heterogeneity could help tailor prevention and treatment strategies for people with depression at greatest metabolic risk.
Open AccessClustering of major depressive disorder genetic instruments identifies distinct and directionally opposing effects on cardiometabolic risk
Background Major depressive disorder (MDD) is a highly heterogeneous condition that is frequently co-morbid with type 2 diabetes (T2D), and yet the biological mechanisms linking these diseases remain unclear. We aim to identify distinct biological pathways in depression that may modify T2D risk. Methods Using Clustered Mendelian randomisation (MR-Clust), we analysed 621 genome-wide significant MDD variants to identify clusters of variants with similar causal effects on T2D. These clusters were validated, and their causal effects were comprehensively tested against glycaemic traits, depression subtypes, T2D risk factors, and cardiometabolic biomarkers using external GWAS data and the UK Biobank. Functional annotation of these clusters was performed using FUMA. Results MR-Clust identified three distinct clusters of MDD-associated variants. Two clusters (MDD1 and MDD2) were causal for higher T2D and its related risk factors, adverse glycaemic and cardiometabolic profiles. Functional annotation implicated brain expression that overlapped strongly with depression-related traits such as smoking and neuroticism. By contrast, MDD3 was causal for lower T2D risk, more favourable glycaemic and cardiometabolic biomarker profiles, and was enriched for gene sets linked to fatty acid metabolism and steroid biosynthesis. MDD1 and MDD2 clusters were associated with atypical-like depression symptoms, whereas MDD3 was associated with melancholic depression symptoms. Conclusion Our findings demonstrate a heterogenous genetic architecture for depression, with distinct biological pathways conferring opposing effects on cardiometabolic health. Understanding this heterogeneity could help tailor prevention and treatment strategies for people with depression at greatest metabolic risk.
- Open Access
Treatment Resistant Depression in electronic health records: Definitions Matter
Background: Many people with depression do not respond well to the first antidepressant prescribed. Treatment Resistant Depression (TRD) refers to depression which does not respond to multiple subsequent antidepressant treatments. Identifying TRD in routinely-collected health records is challenging due to limited response-related data. Previous studies have used definitions based on the number of antidepressant switches observed. However, these do not account for other features clinically indicative of treatment resistance, such as augmentation of antidepressants with lithium or antipsychotics and switches between antidepressant classes. This study examined definitions of TRD and their impact on the resulting sample across three cohorts. Methods: Across the DataLoch, UK Biobank, and Generation Scotland cohorts, we identified cases of depression from primary and secondary care record codes and extracted antidepressant treatment patterns from dispensing/prescribing records (N = 51,283, N = 10,556, and N = 649 respectively). We examined 9 TRD definitions that varied by: the number of switches required (1+, 2+ or 3+ switches), augmentation and between-class switches. We contrasted sample size and characteristics between definitions, and examined factors associated with inclusion versus a reference definition of 2+ switches. Results: The reference TRD definition included 10% of depression cases in the routine data collection, but substantially fewer cases (4%) in consented cohorts. More inclusive definitions that required fewer switches or included a between-class switch classified more individuals as TRD, but resulted in a proportionally older, more deprived sample with fewer depression-related health record codes, older age of depression onset, lower symptom severity, and greater use of first-line antidepressants. Requiring more switches (3+ switches) classified fewer individuals as TRD, but resulted in a proportionally younger sample, with more depression-related health record codes, younger age of depression onset, and greater use of antidepressants associated with later in the treatment line (e.g., Tricyclics). Definitions including augmentations resulted in a small increase in sample size without notable change in sample characteristics. Conclusions: TRD is underrepresented in consented cohort studies. A definition of TRD that includes 2+ antidepressant switches or augmented antidepressant treatment as indicators balances sample size with depression severity, while incorporating features from real-world treatment journeys. Key summary: Treatment Resistant Depression (TRD) is often identified in health records using number of switches in antidepressant treatment, but this misses other important indicators of treatment resistance We examined 9 TRD definitions across 3 cohorts, varying in the number of antidepressant switches, the inclusion of augmented treatment, and the inclusion of between-class switches A TRD definition that included 2+ switches or augmented treatment balanced sample size and severity
Open AccessTreatment Resistant Depression in electronic health records: Definitions Matter
Background: Many people with depression do not respond well to the first antidepressant prescribed. Treatment Resistant Depression (TRD) refers to depression which does not respond to multiple subsequent antidepressant treatments. Identifying TRD in routinely-collected health records is challenging due to limited response-related data. Previous studies have used definitions based on the number of antidepressant switches observed. However, these do not account for other features clinically indicative of treatment resistance, such as augmentation of antidepressants with lithium or antipsychotics and switches between antidepressant classes. This study examined definitions of TRD and their impact on the resulting sample across three cohorts. Methods: Across the DataLoch, UK Biobank, and Generation Scotland cohorts, we identified cases of depression from primary and secondary care record codes and extracted antidepressant treatment patterns from dispensing/prescribing records (N = 51,283, N = 10,556, and N = 649 respectively). We examined 9 TRD definitions that varied by: the number of switches required (1+, 2+ or 3+ switches), augmentation and between-class switches. We contrasted sample size and characteristics between definitions, and examined factors associated with inclusion versus a reference definition of 2+ switches. Results: The reference TRD definition included 10% of depression cases in the routine data collection, but substantially fewer cases (4%) in consented cohorts. More inclusive definitions that required fewer switches or included a between-class switch classified more individuals as TRD, but resulted in a proportionally older, more deprived sample with fewer depression-related health record codes, older age of depression onset, lower symptom severity, and greater use of first-line antidepressants. Requiring more switches (3+ switches) classified fewer individuals as TRD, but resulted in a proportionally younger sample, with more depression-related health record codes, younger age of depression onset, and greater use of antidepressants associated with later in the treatment line (e.g., Tricyclics). Definitions including augmentations resulted in a small increase in sample size without notable change in sample characteristics. Conclusions: TRD is underrepresented in consented cohort studies. A definition of TRD that includes 2+ antidepressant switches or augmented antidepressant treatment as indicators balances sample size with depression severity, while incorporating features from real-world treatment journeys. Key summary: Treatment Resistant Depression (TRD) is often identified in health records using number of switches in antidepressant treatment, but this misses other important indicators of treatment resistance We examined 9 TRD definitions across 3 cohorts, varying in the number of antidepressant switches, the inclusion of augmented treatment, and the inclusion of between-class switches A TRD definition that included 2+ switches or augmented treatment balanced sample size and severity
- Open Access
Understanding antidepressant change patterns in the UK Biobank
Background: Antidepressants are the most prescribed medications in psychiatry. Medical records provide a valuable opportunity to explore prescribing patterns and to uncover clinical and genetic factors that influence treatment outcomes. Methods: Using longitudinal primary care records from the UK Biobank, we investigated antidepressant change patterns in both depression and non-depression indications. We examined outcomes including the number of antidepressant changes, and discontinuation that is likely due to intolerable side effects or inadequate response. Genetic analyses including heritability estimation, genetic correlation and polygenic score association were performed. Results: A total of 82,633 individuals in the UK Biobank were prescribed at least one of 37 antidepressants. Of these, 28,332 had a depression diagnosis and 24,543 did not. Selective serotonin reuptake inhibitors (SSRIs), including citalopram and fluoxetine, were the most prescribed antidepressants for depression, while tricyclic antidepressants, especially amitriptyline, dominated prescriptions in non-depression indications. Individuals with depression were more likely to stay on antidepressants longer than those without depression, and to follow preferred antidepressant choices that have changed over time. For depression, discontinuation rates for SSRIs were 9% for likely intolerable side effects and 12% for likely nonresponse. Antidepressant change and discontinuation were significantly enriched for psychiatric and somatic conditions, including recurrent depression, anxiety in the depression group, and pain-related conditions in the non-depression group. Genetic analyses identified two novel variants associated with SSRI early discontinuation. Notable genetic overlap was shown between these antidepressant phenotypes and multiple psychiatric and physical traits, and polygenic scores had significant prediction for treatment outcomes. Conclusions: These findings provide a valuable framework for characterising antidepressant change in primary care records and highlight the potential of integrating clinical and genetic data to better understand factors influencing treatment outcomes. Replication in other large-scale medical records will be essential to advance the discovery of genetic variants associated with antidepressant outcomes.
Open AccessUnderstanding antidepressant change patterns in the UK Biobank
Background: Antidepressants are the most prescribed medications in psychiatry. Medical records provide a valuable opportunity to explore prescribing patterns and to uncover clinical and genetic factors that influence treatment outcomes. Methods: Using longitudinal primary care records from the UK Biobank, we investigated antidepressant change patterns in both depression and non-depression indications. We examined outcomes including the number of antidepressant changes, and discontinuation that is likely due to intolerable side effects or inadequate response. Genetic analyses including heritability estimation, genetic correlation and polygenic score association were performed. Results: A total of 82,633 individuals in the UK Biobank were prescribed at least one of 37 antidepressants. Of these, 28,332 had a depression diagnosis and 24,543 did not. Selective serotonin reuptake inhibitors (SSRIs), including citalopram and fluoxetine, were the most prescribed antidepressants for depression, while tricyclic antidepressants, especially amitriptyline, dominated prescriptions in non-depression indications. Individuals with depression were more likely to stay on antidepressants longer than those without depression, and to follow preferred antidepressant choices that have changed over time. For depression, discontinuation rates for SSRIs were 9% for likely intolerable side effects and 12% for likely nonresponse. Antidepressant change and discontinuation were significantly enriched for psychiatric and somatic conditions, including recurrent depression, anxiety in the depression group, and pain-related conditions in the non-depression group. Genetic analyses identified two novel variants associated with SSRI early discontinuation. Notable genetic overlap was shown between these antidepressant phenotypes and multiple psychiatric and physical traits, and polygenic scores had significant prediction for treatment outcomes. Conclusions: These findings provide a valuable framework for characterising antidepressant change in primary care records and highlight the potential of integrating clinical and genetic data to better understand factors influencing treatment outcomes. Replication in other large-scale medical records will be essential to advance the discovery of genetic variants associated with antidepressant outcomes.
- Open Access
T-Rx: A toolbox for reproducible processing of prescriptions (Rx) from electronic health records
Linkage between population-wide biobanks and electronic health records (EHRs) opens new opportunities to study the genetic and epidemiological underpinnings of treatment outcomes, a key step forward in delivering precision medicine. However, challenges include complexities in data extraction for longitudinal analyses, and the absence of reproducible phenotyping algorithms. Here, we present T-Rx, an open-source R package to streamline the processing of prescription and dispensing records, to enable reproducible and scalable analysis across EHR databases. T-Rx consists of three modules to derive treatment-related phenotypes from uncleaned prescription records: (1) Extraction and Imputation Module for extracting and imputing prescription details; (2) Exposure Ascertainment Module for converting prescriptions to longitudinal exposure periods; and (3) Phenotyping Module for creating reproducible proxy phenotypes that capture treatment and response patterns. We tested the utility of T-Rx in UK Biobank primary care records, with strength and quantity information extracted and imputed for 2,721,921 antidepressant and 430,705 antipsychotic prescriptions. The extraction functions were validated using oral hypoglycemic agent prescriptions in Clinical Practice Research Datalink Aurum, showing comparable performances to extraction using the NHS Dictionary of Medicines and Devices (dm+d) codes. The Exposure Ascertainment Module of T-Rx converts discrete prescription or dispensing events into longitudinal exposure periods in one-line R commands, with customizable parameters to account for real-world treatment complexities. The Phenotyping Module takes prescriptions as direct user input and returns analysis -ready data frames. Current phenotyping algorithms include antidepressant switching and treatment-resistant depression. The phenotyping functions also allow flexible parameter choices, such as treatment episode windows, definitions for switching and quality control criteria. Researchers can contribute phenotyping algorithms to T-Rx for reproducible use. T-Rx improves the accessibility of prescription information in biobanks, and analysis of dosage- and treatment-patterns across therapeutic areas. T-Rx contributes to open science through harmonized phenotypic definitions and reproducible analyses of proxy treatment outcomes.
Open AccessT-Rx: A toolbox for reproducible processing of prescriptions (Rx) from electronic health records
Linkage between population-wide biobanks and electronic health records (EHRs) opens new opportunities to study the genetic and epidemiological underpinnings of treatment outcomes, a key step forward in delivering precision medicine. However, challenges include complexities in data extraction for longitudinal analyses, and the absence of reproducible phenotyping algorithms. Here, we present T-Rx, an open-source R package to streamline the processing of prescription and dispensing records, to enable reproducible and scalable analysis across EHR databases. T-Rx consists of three modules to derive treatment-related phenotypes from uncleaned prescription records: (1) Extraction and Imputation Module for extracting and imputing prescription details; (2) Exposure Ascertainment Module for converting prescriptions to longitudinal exposure periods; and (3) Phenotyping Module for creating reproducible proxy phenotypes that capture treatment and response patterns. We tested the utility of T-Rx in UK Biobank primary care records, with strength and quantity information extracted and imputed for 2,721,921 antidepressant and 430,705 antipsychotic prescriptions. The extraction functions were validated using oral hypoglycemic agent prescriptions in Clinical Practice Research Datalink Aurum, showing comparable performances to extraction using the NHS Dictionary of Medicines and Devices (dm+d) codes. The Exposure Ascertainment Module of T-Rx converts discrete prescription or dispensing events into longitudinal exposure periods in one-line R commands, with customizable parameters to account for real-world treatment complexities. The Phenotyping Module takes prescriptions as direct user input and returns analysis -ready data frames. Current phenotyping algorithms include antidepressant switching and treatment-resistant depression. The phenotyping functions also allow flexible parameter choices, such as treatment episode windows, definitions for switching and quality control criteria. Researchers can contribute phenotyping algorithms to T-Rx for reproducible use. T-Rx improves the accessibility of prescription information in biobanks, and analysis of dosage- and treatment-patterns across therapeutic areas. T-Rx contributes to open science through harmonized phenotypic definitions and reproducible analyses of proxy treatment outcomes.
- Open Access
Depression increases both glycated haemoglobin testing frequency and risk of all-cause mortality in type 2 diabetes
Background Frequent and consistent Glycated Haemoglobin (HbA1c) measurement is required for effective management of Type 2 diabetes (T2D). Co-morbid depression is an important driver of poor health and mortality in individuals with T2D. Little is known about how engagement with primary care for T2D management differs in individuals with co-morbid depression, and how this impacts all-cause mortality. Methods Adults with T2D were identified in the Clinical Practice Research Datalink Aurum dataset. Glycaemic testing frequency was defined as the number of HbA1c measurements per year after diagnosis. Conway-Maxwell-Poisson mixed effects models were used to test the associations between glycaemic testing frequency and T2D co-morbidities, pre-existing and incident depression (after T2D diagnosis), and depression severity. Cox proportional hazard models were used to determine the association of these variables with all-cause mortality. Results In total, 470,225 individuals with T2D were included. Of these, 20.1% and 6.1% had pre-existing and incident depression, respectively. Younger age, male sex, and non-White self-reported ethnicity were robustly associated with lower glycaemic testing frequency. In contrast, higher deprivation, pre-existing depression (IRR:1.06, CI: 1.05 – 1.07, p = 6.5×10-11), incident depression (IRR:1.04, CI: 1.03 – 1.05, p = 5.5×10-11) and a higher incident comorbidity score were associated with more frequent HbA1c testing. Pre-existing depression, incident depression, and depression severity were associated with increased risk of all-cause mortality after adjusting for HbA1c testing frequency (incident depression HR: 1.41, CI: 1.37 – 1.45, p = 3.7×10-97). In the entire cohort, higher HbA1c testing frequency was associated with reduced risk of all-cause mortality (HR: 0.93, 95% CI: 0.92 – 0.94, p = 3.60×10-82). Conclusion Individuals with T2D and depression have more frequent glycaemic testing yet still face a higher risk of mortality. This suggests that increased engagement with primary care for glycaemic monitoring alone is not sufficient to offset the broader health risks associated with depression. Targeted interventions beyond increased routine diabetes monitoring may be necessary to reduce excess mortality among individuals managing both T2D and depression.
Open AccessDepression increases both glycated haemoglobin testing frequency and risk of all-cause mortality in type 2 diabetes
Background Frequent and consistent Glycated Haemoglobin (HbA1c) measurement is required for effective management of Type 2 diabetes (T2D). Co-morbid depression is an important driver of poor health and mortality in individuals with T2D. Little is known about how engagement with primary care for T2D management differs in individuals with co-morbid depression, and how this impacts all-cause mortality. Methods Adults with T2D were identified in the Clinical Practice Research Datalink Aurum dataset. Glycaemic testing frequency was defined as the number of HbA1c measurements per year after diagnosis. Conway-Maxwell-Poisson mixed effects models were used to test the associations between glycaemic testing frequency and T2D co-morbidities, pre-existing and incident depression (after T2D diagnosis), and depression severity. Cox proportional hazard models were used to determine the association of these variables with all-cause mortality. Results In total, 470,225 individuals with T2D were included. Of these, 20.1% and 6.1% had pre-existing and incident depression, respectively. Younger age, male sex, and non-White self-reported ethnicity were robustly associated with lower glycaemic testing frequency. In contrast, higher deprivation, pre-existing depression (IRR:1.06, CI: 1.05 – 1.07, p = 6.5×10-11), incident depression (IRR:1.04, CI: 1.03 – 1.05, p = 5.5×10-11) and a higher incident comorbidity score were associated with more frequent HbA1c testing. Pre-existing depression, incident depression, and depression severity were associated with increased risk of all-cause mortality after adjusting for HbA1c testing frequency (incident depression HR: 1.41, CI: 1.37 – 1.45, p = 3.7×10-97). In the entire cohort, higher HbA1c testing frequency was associated with reduced risk of all-cause mortality (HR: 0.93, 95% CI: 0.92 – 0.94, p = 3.60×10-82). Conclusion Individuals with T2D and depression have more frequent glycaemic testing yet still face a higher risk of mortality. This suggests that increased engagement with primary care for glycaemic monitoring alone is not sufficient to offset the broader health risks associated with depression. Targeted interventions beyond increased routine diabetes monitoring may be necessary to reduce excess mortality among individuals managing both T2D and depression.
- Top Cited PapersOpen Access
- 10 April 2025
- Published by Elsevier in Biological Psychiatry Global Open Science
- Vol. 5 (4)
Antidepressant Switching as a Proxy Phenotype for Drug Nonresponse: Investigating Clinical, Demographic, and Genetic Characteristics
- 10 April 2025
- Published by Elsevier in Biological Psychiatry Global Open Science
- Vol. 5 (4)
Top Cited PapersOpen AccessAntidepressant Switching as a Proxy Phenotype for Drug Nonresponse: Investigating Clinical, Demographic, and Genetic Characteristics